Global Urinalysis Market
The global urinalysis market in terms of revenue was estimated to be worth $3.9 billion in 2023 and is poised to reach $5.7 billion by 2030, growing at a CAGR of 8.1% from 2023 to 2030. The new research study consists of an analysis of market industry trends. The new research study includes industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behavior in the market. The market growth is driven by increased government emphasis on disease screening, high prevalence of lifestyle-related diseases like diabetes and kidney disease, and increase in diabetes and kidney disease awareness initiatives. related diseases.
Urinalysis Market Dynamics
Driver: Increasing burden of UTIs, diabetes and liver & kidney diseases
Urinalysis is commonly used to diagnose and treat illnesses such as kidney and liver disease. Doctors can use urine analysis to assess the concentration of chemical compounds in the urine. These factors will drive the market ahead.
Opportunity: Emerging market
The high illness incidence, big patient population, expanding healthcare infrastructure, rising disposable income, and growing medical tourism in emerging nations all play important roles in laboratory infrastructure upgrading.
Restraint: Availability of refurbished urine analyzers
In price-sensitive developing nations, affordable equipment with comparable functionality are preferred. In the lack of well-founded regulatory systems, there may be an influx of low-quality and reconditioned items into the economy. These low-cost analyzers will stymie market progress.
Challenge: Changing regulatory landscape for the urinalysis market
In the United States and Europe, regulatory and legal requirements for IVD (including urinalysis) are becoming more stringent. New applications may be required for software updates, new software installation in an existing device, or any other alterations made to these devices. This is a substantial impediment to market growth.
Consumables segment accounted for the largest share of the urinalysis market, by product
The market is divided into two sections: consumables and instruments. The consumables sector accounted for the highest part of the market, owing to rising investment in new diagnostic product development, greater provider knowledge of quick and novel diagnostic technologies, and increased need for rapid illness diagnosis.
Pregnancy & fertility tests segment accounted for the largest share of the urinalysis market, by test type
The market is divided into three categories: pregnancy and fertility testing, biochemical tests, and sediment urinalysis. Due to technical improvements in diagnostic goods, the pregnancy & fertility tests sector accounted for the highest proportion of the market.
Disease screening segment accounted for the largest share of the urinalysis market, by application
The market is divided into two sections: illness screening and pregnancy and fertility. The disease screening segment accounted for the largest share of the market, owing to an ageing population and age-related diseases, emerging economies providing significant growth opportunities, and increased adoption of POC diagnosis, which primarily includes urinalysis for quick and convenient results.
Diagnostic laboratories segment accounted for the largest share of the urinalysis market, by end user
Based on end user, the market is divided into diagnostic laboratories, hospitals & clinics, home care settings, and research laboratories and institutions. The diagnostic labs section held the biggest proportion. Factors such as growing age-related disorders and greater usage of POC analyzers, favourable regulatory standards and reimbursement situations in industrialised nations such as North America and Europe.
North America is the largest regional market for urinalysis market
The global market is divided into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held the greatest proportion of the worldwide market. The rise of the North American market may be ascribed to an increase in illnesses such as diabetes and UTIs, supporting government policies, and significant investment in the development and approval of diagnostic tests for preventive treatment.
Prominent players in urinalysis market are Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), Abbott Laboratories (US), Danaher Corporation (US), Sysmex Corporation (Japan), Quidel Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), EKF Diagnostics (UK), Thermo Fisher Scientific Inc. (US), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (US), 77 ElektronikaKft. (Hungary), URIT Medical Electronic Group Co., Ltd. (China), Dirui Industrial Co., Ltd. (China), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BIOBASE Group (China), ERBA Mannheim (UK), AlphatechScientitfic (Peru), Teco Diagnostics (US), Analyticon Technologies AG (Germany), Bioway Biological Technology Co. Ltd. (China), High Technology Inc. (US) and Agappe Diagnostics Ltd. (India)
By Product
- Consumables
- Instruments
By Test Type
- Pregnancy & Fertility Tests
- Biochemical Urinalysis
- Sediment Urinalysis
By Application
- Disease Screening
- Pregnancy and Fertility
By End User
- Diagnostic Laboratories
- Hospitals and Clinics
- Home Care Settings
- Research Laboratories & Institutes
By Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
- Rest of the World (RoW)
Recent Developments:
- Sysmex Corporation (Japan) announced the UF-1500 fully automated urine particle analyzer, a product for the urine sediment testing area, in September 2022.
- In February 2021, Thermo Fisher Scientific, Inc. (US) and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China) struck a deal to provide toxicology labs with the FDA-cleared and Health Canada-approved BS-480 (400 tests/hour) and BA-800M (800 tests/hour) analyzers.
- Sysmex America, Inc. (a subsidiary of Sysmex Corporation) and Siemens Healthineers AG (Germany) signed an exclusive partnership in August 2020.